Alector ALEC
NASDAQ ALEC
$2.46 -0.05 (-1.99%)
At close: Sep 4, 2026 · 4:00 PM EDT

Alector (ALEC) Liabilities and Shareholders Equity (2018 - 2026)

Alector's (ALEC) quarterly Liabilities and Shareholders Equity came in at $202.9 million in Q2 2026, down 43.09% year-over-year from $356.4 million in Q2 2025, and down 15.45% quarter-over-quarter from $239.9 million in Q1 2026.

Analysis

Alector (ALEC) Liabilities and Shareholders Equity (2018 - 2026) Analysis & Trends

Alector (ALEC) has reported Liabilities and Shareholders Equity for 9 consecutive years, with $202.9 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 43.09% year-over-year to $202.9 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 38.75% decrease from a year earlier, with the FY2025 full-year figure at $293.2 million, down 37.38% from the prior year.
  • Liabilities and Shareholders Equity was $202.9 million for Q2 2026 at Alector, down from $239.9 million in the prior quarter.
  • Over five years, Liabilities and Shareholders Equity peaked at $954.5 million in Q1 2022 and troughed at $202.9 million in Q2 2026.
  • A 5-year average of $569.3 million and a median of $596.3 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
  • Across the five-year window, Liabilities and Shareholders Equity surged 124.03% in 2022 and tumbled 43.09% in 2026, its largest moves.
  • Over 5 years, Liabilities and Shareholders Equity stood at $787.6 million in 2022, then dropped by 21.05% to $621.8 million in 2023, then retreated by 24.69% to $468.3 million in 2024, then slumped by 37.38% to $293.2 million in 2025, then plunged by 30.82% to $202.9 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $202.9 million (Q2 2026), $239.9 million (Q1 2026), and $293.2 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 95.64 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 49.36 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 27.42 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 41.73 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 10.03 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 10.96 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 5.56 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 32.09 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 2.10 Bn
10 Alector 274.68 Mn 101.88 Mn - 202.86 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 202.86 Mn
Mar 31, 2026 239.92 Mn
Dec 31, 2025 293.24 Mn
Sep 30, 2025 335.29 Mn
Jun 30, 2025 356.42 Mn
Mar 31, 2025 408.30 Mn
Dec 31, 2024 468.30 Mn
Sep 30, 2024 516.02 Mn
Jun 30, 2024 570.73 Mn
Mar 31, 2024 635.49 Mn
Dec 31, 2023 621.83 Mn
Sep 30, 2023 672.40 Mn
Jun 30, 2023 708.74 Mn
Mar 31, 2023 748.34 Mn
Dec 31, 2022 787.65 Mn
Sep 30, 2022 837.04 Mn
Jun 30, 2022 889.67 Mn
Mar 31, 2022 954.46 Mn
Dec 31, 2021 814.66 Mn
Sep 30, 2021 854.23 Mn